Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Figure 6

Meta-analysis of the incidence of neoplasia with the use of a GLP-1 receptor agonist versus placebo or other antidiabetic treatments, based on studies with a minimum duration of 3 years.